TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16574922

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 90 microg/kg desmoteplase
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 125 microg/kg desmoteplase
Number of subjects: 37
Study: 14560188

Group type: EXPERIMENTAL
Intervention: Disc Replacement
Number of subjects: 53

Group type: COMPARATOR
Intervention: Fusion
Number of subjects: 53
Study: 10671887

Group type: EXPERIMENTAL
Intervention: Left spermatic vein ligation
Number of subjects: 68

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 68
Study: 9107169

Group type: EXPERIMENTAL
Intervention: CPI waveform with 60% positive‐phase (P1) tilt and 50% negative‐phase (P2) tilt
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Medtronic waveform with 65% fixed tilt in both P1 and P2
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ventritex waveform with 60% P1 tilt and a P2 leading edge voltage equal to half of the P1 trailing edge voltage
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Biphasic waveforms with equal P1 tilt at 65% but shorter P2 duration or smaller P2 peak voltage
Number of subjects: 42
Study: 7513512

Group type: EXPERIMENTAL
Intervention: Tranilast 300 mg daily for 6 to 7 weeks before the onset of the pollen season and continuously during the season
Number of subjects: 38

Group type: COMPARATOR
Intervention: No medication including tranilast until the onset of clinical symptoms in season
Number of subjects: 38
Study: 3743153

Group type: EXPERIMENTAL
Intervention: albuterol administered by metered‐dose inhaler
Number of subjects: 19

Group type: COMPARATOR
Intervention: albuterol administered by ultrasonic nebulizer
Number of subjects: 19

Group type: COMPARATOR
Intervention: Freon (placebo effect from metered‐dose inhaler)
Number of subjects: 19

Group type: COMPARATOR
Intervention: isotonic saline solution (placebo effect from ultrasonic nebulizer)
Number of subjects: 19
Study: 30343620

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27886073

Group type: EXPERIMENTAL
Intervention: Diet intervention (300-500 kcal/day less energy intake, optimized nutrient composition, three face-to-face counseling sessions, online supervision 1-3 times per week)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Diet intervention
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (maintain habitual lifestyle)
Number of subjects: 49
Study: 24962185

Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose sodium hyaluronate adhesion barrier (CMHAB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No adhesion barrier (NAB)
Number of subjects: 30
Study: 22652985

Group type: EXPERIMENTAL
Intervention: Standard rehabilitation plus NMES applied 2 times per day at maximal tolerable intensity for 15 contractions for 6 weeks after TKA.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Standard rehabilitation plus NMES
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 30
Study: 20137069

Group type: EXPERIMENTAL
Intervention: Higher PICOT score
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Structured research question
Number of subjects: 89
Study: 18672629

Group type: EXPERIMENTAL
Intervention: 0.9 mg of atropine plus 2.5 mg of neostigmine
Number of subjects: 46

Group type: COMPARATOR
Intervention: 1.2 mg of atropine plus 2.5 mg of neostigmine
Number of subjects: 46
Study: 16528650

Group type: EXPERIMENTAL
Intervention: Liquid fatty meal
Number of subjects: 84

Group type: COMPARATOR
Intervention: Non-fat meal
Number of subjects: 84
Study: 12650950

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg b.i.d.
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg b.i.d.
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg)
Number of subjects: 175
Study: 11147930

Group type: EXPERIMENTAL
Intervention: Amantadine treatment
Number of subjects: 16
Study: 8741958

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg cocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg cocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5.0 mg placebo
Number of subjects: 0
Study: 1422928

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cimetidine 200 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Diazepam only
Number of subjects: 33
Study: 4048254

Group type: EXPERIMENTAL
Intervention: Ampicillin (X)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ampicillin (Helm)
Number of subjects: 9
Study: 30056384

Group type: EXPERIMENTAL
Intervention: Mechanical chest compression device
Number of subjects: 4471
Study: 27050475

Group type: EXPERIMENTAL
Intervention: Early intervention treatment
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Baseline characteristics (male gender, unemployment, poor premorbid achievement, later age of onset)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Negative symptoms amelioration
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Symptom scores
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Cognitive tests
Number of subjects: 322
Study: 25651378

Group type: EXPERIMENTAL
Intervention: Fentanyl alone (5 microgram per kilogram)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fentanyl plus ketoconazole (200 milligram orally B.I.D. over 2 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ketoconazole
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Midazolam (CYP3A probe drug)
Number of subjects: 16
Study: 23842591

Group type: EXPERIMENTAL
Intervention: Low-dose triiodothyronine (0.5 mcg/kg orally every 24 hr for 3 days)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: High-dose triiodothyronine (0.5 mcg/kg orally every 12 hr for 3 days)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 20702794

Group type: EXPERIMENTAL
Intervention: Lithium carbonate at therapeutic levels (0.4‐0.8 mEq/L)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Lithium carbonate at subtherapeutic levels (0.2‐0.4 mEq/L)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Both therapeutic and subtherapeutic lithium carbonate
Number of subjects: 171
Study: 18157835

Group type: EXPERIMENTAL
Intervention: Silymarin (milk thistle extract)
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Nonusers of silymarin
Number of subjects: 1145
Study: 16263254

Group type: EXPERIMENTAL
Intervention: beta(2)-agonist therapy
Number of subjects: 80
Study: 14597974

Group type: EXPERIMENTAL
Intervention: Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) at doses ranging from 0.3 to 5 micro g/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant Nematode Anticoagulant Protein c2 (rNAPc2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bovine factor X interaction
Number of subjects: 0
Study: 10862388

Group type: EXPERIMENTAL
Intervention: Nabumetone (Relafen)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9276053

Group type: EXPERIMENTAL
Intervention: Cryotherapy (Cryo/Cuff, AirCast, Summit, NJ)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no cryotherapy)
Number of subjects: 15
Study: 1486159

Group type: EXPERIMENTAL
Intervention: Lignocaine spray 50 mg (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lignocaine spray 100 mg (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lignocaine spray 200 mg (Group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no lignocaine spray)
Number of subjects: 60
Study: 3815751

Group type: EXPERIMENTAL
Intervention: Specialized education
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (no specialized education)
Number of subjects: 82
Study: 31316254

Group type: EXPERIMENTAL
Intervention: Screw PFN
Number of subjects: 60

Group type: COMPARATOR
Intervention: Helical PFN
Number of subjects: 60
Study: 27868366

Group type: EXPERIMENTAL
Intervention: gemigliptin
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 25336730

Group type: EXPERIMENTAL
Intervention: ChAd63-MVA CS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ChAd63-MVA ME-TRAP
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 30
Study: 23265758

Group type: EXPERIMENTAL
Intervention: Novel injection approach
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional injection approach
Number of subjects: 40
Study: 21764203

Group type: EXPERIMENTAL
Intervention: Continuation of warfarin without interruption (group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Warfarin bridged with low-molecular-weight heparin (group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Warfarin bridged with unfractionated heparin (group 3)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group of healthy individuals (group 4)
Number of subjects: 40
Study: 19295955

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte drink containing 36.2 mmol/L sodium (HNa)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte drink containing 19.9 mmol/L sodium (LNa)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Mineral water (W)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Colored and flavored distilled water (PL)
Number of subjects: 13
Study: 17077623

Group type: EXPERIMENTAL
Intervention: High plasma levels of C-reactive protein (CRP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MPO and VEGF levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRP and interleukin-6 levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MPO
Number of subjects: 0
Study: 14759641

Group type: EXPERIMENTAL
Intervention: Acetyl L-carnitine (ALCAR) 1 g twice daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Amantadine 100 mg twice daily
Number of subjects: 36
Study: 11455175

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 9447899

Group type: EXPERIMENTAL
Intervention: Meropenem (1 g t.i.d.)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Imipenem/cilastatin (1 g t.i.d.)
Number of subjects: 151
Study: 7639373

Group type: EXPERIMENTAL
Intervention: Subcutaneous lidocaine (10 mL 1%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subfascial lidocaine (10 mL 1%)
Number of subjects: 0
Study: 3358883

Group type: EXPERIMENTAL
Intervention: Calcium carbimide (CC) 50 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31789541

Group type: EXPERIMENTAL
Intervention: HTUG + IPT
Number of subjects: 52

Group type: COMPARATOR
Intervention: IPT-Only
Number of subjects: 52
Study: 29438682

Group type: EXPERIMENTAL
Intervention: Serum copper concentrations >24 μmol/L
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Height (5th percentile or greater)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Serum zinc and copper concentrations
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Dietary zinc intake
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Dietary copper intake
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Serum copper concentration
Number of subjects: 408
Study: 27349410

Group type: EXPERIMENTAL
Intervention: Thresholds determined from training set using AOD750 inferiorly at 0.31 mm threshold
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Thresholds determined from training set using TICV500 at 1.92 μL
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Thresholds determined from training set using TICV750 at 4.00 μL
Number of subjects: 189
Study: 25899420

Group type: EXPERIMENTAL
Intervention: Octenidine-based dressings
Number of subjects: 80

Group type: COMPARATOR
Intervention: Silver dressings
Number of subjects: 80
Study: 24084533

Group type: EXPERIMENTAL
Intervention: Vaginal colpopexy repair with mesh
Number of subjects: 65

Group type: COMPARATOR
Intervention: Traditional vaginal prolapse surgery without mesh
Number of subjects: 65
Study: 21390318

Group type: EXPERIMENTAL
Intervention: Personalized cooling protocol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: BAT-positive subjects (n=26)
Number of subjects: 15
Study: 18309945

Group type: EXPERIMENTAL
Intervention: Doxorubicin with dexrazoxane (n = 105)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Doxorubicin alone (n = 100)
Number of subjects: 205
Study: 17136298

Group type: EXPERIMENTAL
Intervention: Leukotriene antagonists (LTA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids + long‐acting Beta2 agonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study: 12702125

Group type: EXPERIMENTAL
Intervention: Silicone-based sealer
Number of subjects: 199

Group type: COMPARATOR
Intervention: Grossman's sealer
Number of subjects: 199
Study: 10810776

Group type: EXPERIMENTAL
Intervention: Transcoronary ablation of septum hypertrophy (TASH)
Number of subjects: 187
Study: 8821373

Group type: EXPERIMENTAL
Intervention: Memantine (20 mg, single-dose application)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1563211

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms as a single dose or q.i.d. as a multiple dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Indomethacin (100 mg single-dose administration or 50 mg t.i.d. multiple-dose administration)
Number of subjects: 16
Study: 6860527

Group type: EXPERIMENTAL
Intervention: Long-acting propranolol 160 mg daily
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional propranolol 80 mg twice daily
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional propranolol 160 mg daily
Number of subjects: 11
Study: 29807629

Group type: EXPERIMENTAL
Intervention: Subdissociative intravenous-dose ketamine (SDK) at 0.3 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine at 0.1 mg/kg
Number of subjects: 60
Study: 29617375

Group type: EXPERIMENTAL
Intervention: Bandebereho intervention
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1199
Study: 27560168

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 68
Study: 24493296

Group type: EXPERIMENTAL
Intervention: Single-stage treatment (laparoscopic cholecystectomy and CBD exploration at the same operation)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Two-stage treatment (endoscopic stone clearance followed by laparoscopic cholecystectomy 2-5 days later)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Two-stage treatment
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Single-stage treatment
Number of subjects: 221
Study: 19261314

Group type: EXPERIMENTAL
Intervention: Artesunate+sulfadoxine/pyrimethamine (AS+SP) (4 mg/kg AS for 3 consecutive days+25 mg sulfadoxine on Day 0)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Praziquantel (PZQ) (40 mg/kg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Artesunate+sulfadoxine/pyrimethamine (AS+SP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Praziquantel (PZQ)
Number of subjects: 46
Study: 15867120

Group type: EXPERIMENTAL
Intervention: Practice-based quality improvement intervention (coaching practice staff in auditing performance and implementing new care processes)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Practice-based quality improvement intervention
Number of subjects: 44
Study: 11561925

Group type: EXPERIMENTAL
Intervention: Expressive writing about thoughts and feelings regarding coming to college
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Expressive writing about a negative personal experience
Number of subjects: 69

Group type: COMPARATOR
Intervention: Writing about a positive experience
Number of subjects: 69

Group type: COMPARATOR
Intervention: Writing about a trivial topic
Number of subjects: 69
Study: 9853200

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Donepezil 10 mg/day
Number of subjects: 0
Study: 7922999

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial embolization (TAE) with cisplatin (50 mg) mixed with Lipiodol (5-15 ml) and gelfoam pieces.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Transcatheter arterial embolization (TAE) with Lipiodol and gelfoam pieces only (control group).
Number of subjects: 46
Study: 3072223

Group type: EXPERIMENTAL
Intervention: Nifedipine 5 mg 3 times daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg 3 times daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12501067

Group type: EXPERIMENTAL
Intervention: Active magnets (500 G) applied to abdominal trigger points for 24 hours per day for 4 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo magnets
Number of subjects: 32
Study: 31756716

Group type: EXPERIMENTAL
Intervention: Mindfulness training with daily text prompts to practice mindfulness for 10 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving a placebo message
Number of subjects: 0
Study: 29846278

Group type: EXPERIMENTAL
Intervention: Cooling treatment (cooling gel cuff)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control (sham control cuff)
Number of subjects: 276
Study: 26714233

Group type: EXPERIMENTAL
Intervention: BSAFER Web-based program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Web-based control program
Number of subjects: 40
Study: 24687385

Group type: EXPERIMENTAL
Intervention: PTH(1-84) 100 μg/d s.c.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 22583743

Group type: EXPERIMENTAL
Intervention: Nebulized tobramycin
Number of subjects: 553

Group type: COMPARATOR
Intervention: Dry powder device for inhaled tobramycin
Number of subjects: 553
Study: 20345956

Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation and/or nutritional supplementation
Number of subjects: 116

Group type: COMPARATOR
Intervention: Stunted group
Number of subjects: 116

Group type: COMPARATOR
Intervention: Non-stunted group
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Stunted children
Number of subjects: 116
Study: 18848176

Group type: EXPERIMENTAL
Intervention: Electronic monitoring of drug adherence (Medication Event Monitoring System)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 68
Study: 15753751

Group type: EXPERIMENTAL
Intervention: Isoflurane with active scavenging
Number of subjects: 15

Group type: COMPARATOR
Intervention: Isoflurane without active scavenging
Number of subjects: 15
Study: 12439472

Group type: EXPERIMENTAL
Intervention: Index of Orthodontic Treatment Need (IOTN) instruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-control group
Number of subjects: 0
Study: 10037249

Group type: EXPERIMENTAL
Intervention: GH treatment at a daily dose of 0.1 IU/kg (n=26) or 0.2 IU/kg (n=7) body weight
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 33
Study: 8947323

Group type: EXPERIMENTAL
Intervention: 3 hours of cognitive behavioral counseling over 1 year
Number of subjects: 105

Group type: COMPARATOR
Intervention: Advice to reduce alcohol intake
Number of subjects: 105
Study: 2015150

Group type: EXPERIMENTAL
Intervention: 4% isoflurane in oxygen
Number of subjects: 75

Group type: COMPARATOR
Intervention: Traditional techniques using nitrous oxide and gradually increasing inspired vapour concentration
Number of subjects: 75
Study: 7127998

Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg b.i.d. for 12 weeks, increased to 0.2 mg for 12 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (24 mg b.i.d. for 12 weeks, increased to 50 mg for 12 weeks)
Number of subjects: 29
Study: 31793688

Group type: EXPERIMENTAL
Intervention: Peer‐Led Asthma Self‐Management Program for Adolescents (PLASMA)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 259
Study: 30675742

Group type: EXPERIMENTAL
Intervention: Pharmacist-led telephone follow-up (TFU) intervention
Number of subjects: 0
Study: 30506536

Group type: EXPERIMENTAL
Intervention: Bladder training group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Bladder non-training group
Number of subjects: 92
Study: 27176465

Group type: COMPARATOR
Intervention: Price reduction
Number of subjects: 644

Group type: COMPARATOR
Intervention: Combined skill-building and price reduction
Number of subjects: 644

Group type: COMPARATOR
Intervention: Skill-building
Number of subjects: 644

Group type: COMPARATOR
Intervention: Combined intervention
Number of subjects: 644
Study: 25133855

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Internet-based guided self-help
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Therapist adherence
Number of subjects: 89
Study: 22243774

Group type: EXPERIMENTAL
Intervention: S-1/oxaliplatin (SOX)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Capecitabine/oxaliplatin (CAPOX)
Number of subjects: 129
Study: 19648568

Group type: EXPERIMENTAL
Intervention: CAI (computer‐assisted instruction) using DVD technology
Number of subjects: 73

Group type: COMPARATOR
Intervention: Traditional laboratory instruction
Number of subjects: 73
Study: 17218618

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 4 to 6 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control subjects (matched healthy control subjects)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Patients with OSA before CPAP therapy
Number of subjects: 8
Study: 15891124

Group type: EXPERIMENTAL
Intervention: 100 mg thalidomide daily for one week, followed by 50 mg/day for weeks 2 and 3, then dummy capsules in weeks 4 through 7.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 300 mg thalidomide daily for one week, followed by gradual decrements every two weeks.
Number of subjects: 22
Study: 12499621

Group type: EXPERIMENTAL
Intervention: Thallium-201 myocardial scintigraphy (Tl-201)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Heart-to-mediastinum (H/M) MIBG uptake ratio
Number of subjects: 47

Group type: COMPARATOR
Intervention: Percent washout ratio of myocardial MIBG
Number of subjects: 47